# Evaluation of Safety of Pomalidomide in Combination With Dexamethasone (Low Dose) in Patients With Refractory or Relapsed and Refractory Multiple Myeloma

> **NCT01712789** · PHASE3 · COMPLETED · sponsor: **Celgene** · enrollment: 682 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Pomalidomide
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT01712789
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-11-06
- **Primary completion:** 2019-12-11
- **Final completion:** 2019-12-11
- **Target enrollment:** 682 (ACTUAL)
- **Last updated:** 2022-01-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01712789

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01712789, "Evaluation of Safety of Pomalidomide in Combination With Dexamethasone (Low Dose) in Patients With Refractory or Relapsed and Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01712789. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*